Medical marijuana, immunotherapy: Treating cancer without the ill side-effects

The road to treating cancer has always been a long winding, uncertain road. It seems that year after year, there’s a “fad cure” that would always present hope, but not all of them deliver the expected results in the long run. Some have been quite successful, some, not so much. However, there are two cures that scientists, researchers, and even investors are banking on for potential returns: marijuana and immunotherapy.

Marijuana as a cancer cure has always been dealt with two sides. In the United States, doctors in four states prescribe its use to ease symptoms brought about by chemotherapy in cancer patients. In other parts of the world, recommending the use of marijuana as a cancer cure wouldn’t even be a possibility.

Medical marijuana dispensary. (Source)

Recent multiple reports state that government-funded, The National Institute on Drug Abuse officially admitted that marijuana kills cancer cells. The institute revised a portion of its website on marijuana’s medicinal use, citing a study conducted by scientists in London’s St. George University. The study stated: “Recent animal studies have shown that marijuana extracts may help kill certain cancer cells and reduce the size of others. One cell culture study suggests that purified extracts from whole-plant marijuana can slow the growth of cancer cells from one of the most serious types of brain tumors.”

Immunotherapy is another promising cancer cure that focuses on stimulating the immune system through artificial vaccines or proteins, allowing the body to fight the cancer from within. TV program 60 Minutes noted that it’s “a big leap forward,” while an HBO documentary on cancer cures called “Vice,” said that aside from being “miraculous,” immunotherapies put the human race “on the verge of curing cancer.” Doctors witness how deadly tumors in terminal patients disappear, allowing them to go into remission for longer years.

The results gained from immunotherapy garnered so much praise that the stock market believes that it should have its own index. Forbes reported that longtime immunotherapy investor, Brad Loncar, rounded up all major players and emerging companies in the biotech field to create this index. Called the Loncar Cancer Immunotherapy Index, it includes 25 companies spearheading the immunotherapy race. The index includes Merk, Bristol-Myers Squibb, and smaller ones such as Kite Pharma, Juno Therapeutics. Investors who bank on the emerging biotech sector include those with PhDs and MDs. “I want to repackage biotech in a way that ordinary people can understand it,” said Loncar to Forbes.

Nascent Biotech, Inc. (OTC:NBIO) is a California-based research company that has developed a natural human antibody called Pritumumab. The antibody is derived using proprietary technology from a B-Cell isolated from a tumor draining lymph node of a patient with cervical cancer. So far, it has been used to cure 250 brain cancer patients. With the steady success of Pritumumab, it won’t be long until Nascent Biotech, Inc. finds itself on the Loncar Cancer Immunotherapy Index.

Positive results brought about by medical marijuana and immunotherapy lead to a growing awareness that cancer can be treated in natural ways. They also signal a new chapter for patients who wish to gain respite from or stop chemotherapy altogether.

Nascent Biotech, Inc.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.